Results 221 to 230 of about 180,865 (263)

Catequentinib/programmed-cell-death-1-receptor-antagonists

Reactions Weekly, 2023
openaire   +1 more source

Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody

Cancer Control, 2022
Bo Hao, Qing Geng
exaly  

Antineoplastics/programmed-cell-death-1-receptor-antagonists

Reactions Weekly, 2023
openaire   +1 more source

Antineoplastics/programmed-cell-death-1-receptor-antagonists

Reactions Weekly, 2022
openaire   +1 more source

Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1

Recent Patents on Anti-Cancer Drug Discovery, 2021
Lu Jiang
exaly  

Programmed-cell-death-1-receptor-antagonists/rivoceranib

Reactions Weekly, 2020
openaire   +1 more source

Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti‐CD19‐chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B‐cell lymphoma and high tumor burden

Hematological Oncology, 2023
Juan Mu, Jijun Yuan, Qing Li
exaly  

The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis

International Immunopharmacology, 2020
Hao Hu
exaly  

Programmed cell death 1 receptor antagonists

Reactions Weekly
openaire   +2 more sources

Programmed cell death-1 receptor antagonists/vemurafenib

Reactions Weekly, 2020
openaire   +1 more source